MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.78
-0.47 (-3.84%)
At close: Jan 30, 2026, 4:00 PM EST
11.85
+0.07 (0.59%)
After-hours: Jan 30, 2026, 6:19 PM EST

MiNK Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-12.36-10.78-22.46-27.99-30.21-16.24
Depreciation & Amortization
0.20.220.20.120.080.06
Loss (Gain) From Sale of Assets
0.17-0.19----
Stock-Based Compensation
2.51.813.863.031.740.09
Other Operating Activities
1.11-1.07-0.27-2.7911.836.28
Change in Accounts Payable
1.33-1.18-1.922.66-0.150.61
Change in Unearned Revenue
------0.19
Change in Other Net Operating Assets
1.461.644.816.113.891.06
Operating Cash Flow
-5.58-9.56-15.76-18.87-12.83-8.34
Capital Expenditures
---0.07-0.25-0.25-0.1
Investing Cash Flow
---0.07-0.25-0.25-0.1
Long-Term Debt Issued
-5--9.4611.11
Net Debt Issued (Repaid)
-5--9.4611.11
Issuance of Common Stock
13.555.820.070460
Repurchase of Common Stock
---0.48-0.16--
Other Financing Activities
-----6.2-
Financing Cash Flow
13.5510.82-0.41-0.1649.2611.11
Foreign Exchange Rate Adjustments
-0.01-0.05-0.030.020.02-0.28
Net Cash Flow
7.951.21-16.27-19.2536.22.39
Free Cash Flow
-5.58-9.56-15.84-19.12-13.08-8.43
Free Cash Flow Per Share
-1.36-2.53-4.61-5.68-5.02-3.50
Cash Interest Paid
0.010.010.030.01--
Levered Free Cash Flow
-4.78-8.62-11.08-20.25-8.67-2.21
Unlevered Free Cash Flow
-4.78-8.62-11.08-20.25-7.15-0.68
Change in Working Capital
2.80.462.98.773.741.48
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q